Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Oracle Named Top Software Vendor for Life Sciences

By Drug Discovery Trends Editor | June 22, 2009

In a new report, IDC Health Insights, an advisory services and market research firm focused on the healthcare and life science markets, ranked Oracle as the number one vendor for enterprise life sciences software applications. The Life Science Software Top 10 identifies the 10 leading enterprise and specialty software vendors serving the sector based on enterprise life science software license revenue.

The report cites Oracle’s increased commitment and focus on life sciences for driving its leading share of the $2.95 billion that IDC Health Insights estimates is spent annually on software in the life sciences sector. According to report, “Oracle easily topped the chart, with nearly $60 million more than the second-place SAP.” The ranking is based solely on software license revenue derived from life sciences customers, and the study examined only enterprise solutions, which included: business intelligence/analytics, clinical software, customer relationship management (CRM), content management, revenue management/enterprise resource planning (ERP), human resources (HR), manufacturing, supply chain management, product lifecycle management (PLM), research and development (R&D) informatics and R&D discovery platforms.

“Oracle’s fast-paced acquisition strategy, coupled with its increased commitment and focus on the life sciences via its new Health Sciences Global Business Unit has paid big dividends, which have helped to drive its success in the life science industry,” wrote Eric Newmark, Research Manager, IDC Health Insights, in the report.

Date: June 22, 2009
Source: Oracle 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50